{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"DLTs were to be assessed based on the National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.3 (NCI-CTCAE v 4.3). DLTs: drug-related toxicities that meet any one of the following criteria: Grade 4 thrombocytopenia; Grade 3 thrombocytopenia with bleeding; Grade 4 neutropenia continuing for greater than or equal to (\\>/=) 7 consecutive days or neutropenic fever; Non-hematological toxicity of Grade 3 or higher; Adverse events that require interruption of treatment for a total of \\>/=7 days.","groups":[{"description":"Participants received alectinib at a dose of 600 mg via capsule, orally, twice daily, continuously starting on Day 1 Cycle 1 (in 28-day cycles) until PD, death, or withdrawal for any other reasons, whichever occurred first. After PD, participants were allowed to continue treatment with alectinib as per the discretion of the treating physician.","id":"OG000","title":"Alectinib"}],"populationDescription":"The endpoint was not analyzed in this study as the RP2D was confirmed in study NP28761 (NCT01871805).","reportingStatus":"POSTED","timeFrame":"Cycle 1 (up to 28 days)","title":"Percentage of Participants With Dose Limiting Toxicities (DLTs)","type":"PRIMARY"}